anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A traumatic brain injury (TBI) is caused by a strong blow, jolt, or penetration to the head that disrupts normal brain functioning. A TBI can range from a mild concussion to severe brain damage. Falls, assaults, and motor vehicle accidents account for more than 50% of TBIs. Physical symptoms of a TBI can be subtle to severe and can include nausea, memory loss, mood swings, blurred vision, and light-headedness. This type of injury can be very stressful for families and can result in feelings of anxiety, burden, and depression among family members. A child who experiences a TBI will often display new social and behavioral problems, leading to further parental distress and increased family dysfunction. Recent studies have shown that problem-solving interventions can reduce caregiver distress and improve child adjustment following a TBI. However, access to skilled therapists and specialized care for this kind of psychosocial treatment is often limited in many communities. In such communities, the Internet offers a new way to meet the mental and other health needs of individuals with TBIs. This study will evaluate the effectiveness of an Internet-based psychosocial treatment in improving problem solving, communication skills, stress management strategies, and coping among teens who have had a TBI and their families.

Families participating in this study will be randomly assigned to either an Internet-based counselor-assisted problem-solving (CAPS) group or an Internet resource comparison group (IRC). Participants assigned to CAPS will work with a trained counselor who will guide them through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions. Families assigned to IRC will receive computers, high speed Internet access, and links to brain injury information and resources, but no access to the CAPS Web site content. The effectiveness of CAPS will be assessed after treatment and at 6- and 12-month follow-up evaluations.
BACKGROUND: Cervical cancer is a global public health problem with high mortality. Advances in screening programs for cervical cancer are considered key to eliminate cervical cancer. We aimed to examine the contribution of cell block analysis to the detection of epithelial cell abnormalities in cervical smear samples.
METHODS: A total of 559 patients with suspected cervical pathology were examined, and their samples were analyzed by both liquid-based cytology (LBC) and cell blocks. The biopsy results of 149 out of the 559 patients were obtained.
RESULTS: Of the 50 patients who were identified as HSIL by biopsy, only 12 were diagnosed as HSIL by the LBC method, 22 as LSIL, 12 as ASCUS, and 4 as ASC-H (p < 0.001). With the cell block analysis, results for these patients were: 20 HSIL, 17 LSIL, 7 NILM, 4 'unsatisfactory', and 2 ASC cases (p < 0.001). LBC detected only 1 of the 10 patients with biopsy-diagnosed tumors, while 7 of these were defined as HSIL, 1 as ASCUS and 1 as AGC. The results of cell block analysis in patients with biopsy-diagnosed tumors were as follows: 7 HSIL, 1 tumor, 1 ASC and 1 LSIL.
CONCLUSIONS: Cell block analysis might be superior to LBC in terms of diagnostic accuracy in cervical pathologies, particularly in the detection of HSIL. However, both methods were similarly poor in diagnosing tumors. Cell blocks may improve diagnostic accuracy and can be a complementary method to LBC, while having the advantage of revealing histological architecture.
Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
The relationship between pain and alcohol use disorder (AUD) is complex and bidirectional. The current study examines risk factors for pain in a large comprehensively phenotyped sample including individuals from across the spectrum of alcohol use and misuse. Participants (n = 1101) were drawn from the National Institute on Alcohol Abuse and Alcoholism Natural History Protocol and included treatment-seeking AUD inpatients (AUD+Tx, n = 369), individuals with AUD not seeking treatment (AUD+, n = 161), and individuals without AUD (AUD-, n = 571). General linear models were utilized to test the effects of AUD status, history of childhood trauma exposure, perceived stress, and psychological comorbidity on daily percent time in pain, as well as change in daily percent time in pain across the inpatient stay in AUD+Tx individuals. Overall, 60.2% individuals reported any pain, with a significantly higher prevalence in the AUD+Tx group (82.1%) compared to the AUD+ (56.5%) and AUD- (47.1%) groups. Daily percent time in pain was also highest in the AUD+Tx group (30.2%) and was further increased in those with a history of childhood abuse and comorbid posttraumatic stress disorder (PTSD). Years of heavy drinking and craving were also associated with increased percent time in pain in the AUD+Tx group. Percent time in pain decreased following acute withdrawal in the AUD+Tx group but plateaued around 25% just prior to discharge. Individuals seeking inpatient treatment for AUD, especially those with a history of childhood trauma and/or comorbid PTSD, report greater percent time in pain compared to those not seeking treatment and those without AUD. The prolonged experience of pain in abstinent AUD inpatients after the resolution of acute withdrawal may signal the early stages of protracted withdrawal. Integrative treatments targeting pain and other symptoms of protracted withdrawal may be effective in improving overall function in people with severe AUD.
Despite its potential clinical impact, the association of personal neglect (PN) with motor, activities of daily living (ADL), and participation outcomes after stroke is not well-understood. This first-ever systematic review on the topic therefore evaluates this association, taking into account suggested subtypes of PN, including body representation neglect, somatosensory neglect, motor neglect, and premotor neglect. A systematic literature search was conducted on February 17, 2023 in PubMed, Web of Science, Scopus, PubPsych, and PsycArticles databases. The study adheres to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and its protocol was registered on PROSPERO (CRD42020187460). Eleven observational studies were included, gathering 1,400 individuals after stroke (429 showed PN). Results show that individuals with body representation neglect after stroke have significantly decreased movement control and motor strength, lower functional mobility, and ADL independency compared with those without body representation neglect after stroke. Individuals with motor neglect after stroke showed worse motor function and spasticity than to those without motor neglect after stroke. Nonspecified PN (i.e., PN evaluated with an outcome measure that does not allow subcategorization) was related to worse lateropulsion with pushing, longer length of stay and greater odds of being discharged to somewhere other than home. No study evaluated somatosensory and premotor neglect. This review highlights the limited research in this area and emphasizes the need for a more comprehensive PN assessment. However, currently available assessment tools show limited ability to accurately diagnose PN subtypes and future research should prioritize the development of comprehensive diagnostic test batteries.
Participants will receive Treatment C \[JNJ-54175446, 100 mg capsule\] on Day 1 of period 1 followed by Treatment D \[JNJ-54175446, 100 mg suspension\] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
The present invention provides a perfume field which is formed by using soda water as a carrier, and matching three vitamins b and c and a plant extract c according to a proportion. The soda water is 0.4 percent of soda water, and b consisting of the three vitamins b and c is natural vitamin b1, b2, b5 and vitamin c; the plant extract c is lavender oil and rose extract. The bacteriostatic skin-care mosquito-repellent perfume prepared according to the scheme of the invention adopts the alkalescence of soda water to inhibit and balance the acidity of eubacteria generated by a human body, thereby killing and inhibiting the propagation of the eubacteria. Thereby also eliminating the sweat odor of the human body. The natural vitamins b1, b2 and b5, the vitamin c, the lavender oil and the rose extract have the functions of protecting the skin and protecting the skin, protecting the skin from damage and anaphylactic reaction and repairing the skin; the vitamin quilt b1, 2, lavender oil and rose extract also have the effect of preventing mosquitoes. All formulas of the antibacterial skin-care anti-mosquito perfume are refined by adopting edible and pure natural substances, and the antibacterial skin-care anti-mosquito perfume not only has the functions of bacteriostasis, skin care and anti-mosquito, but also is synergistically complementary with the metabolism of a human body. Has no pollution and anaphylactic reaction, and is suitable for people of any constitution and any age group.
Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week "washout" period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs.
A crystalline ziprasidone camsylate half hydrate is provided to have formulation property and stability by not absorbing moisture. A method for manufacturing a crystalline ziprasidone camsylate half hydrate of the chemical formula 1 comprises: a step of reacting ziprasidone and camphorsulfonic acid in inert solvent; and a step of cooling to -10~10 °C and adding distilled water to form crystalline structure. The inert solvent is aceton, ethyl acetate, methanol, ethanol, isopropanol, acetonitrile, isopropyl ether, methyl ethyl ketone, dichloromethane, tetrahydrofuran or their mixture. The crystalline ziprasidone camsylate half hydrate has more than 97.0% of yield and 99.0% of purity. A pharmaceutical composition of schizophrenia or the bipolar disorder related mania comprises the crystalline ziprasidone camsylate half hydrate and pharmaceutically allowable carrier. The composition is used in a form of granule, powder, liquid, tablet, capsule or oral formulation.
FIELD: medicine. SUBSTANCE: perfluorane is introduced once into patient's body but preliminary estimation of macro- and microdynamics nature of lower limbs should be conducted. At occlusion of main vessels perfluorane is injected intravenously at the dose of 200 ml. At occlusion of peripheral vessels perfluorane is preoxygenized for 5 minutes by gaseous oxygen to be injected into femoral artery of injured limb by punctures with the help of automatic batcher for medicinal substances. At infringed rheological blood properties anticoagulants or angioprotectors are additionally introduced. Method enables to decrease ischemic manifestations in a limb, demarcation area is developed at purulent-necrotic lesion of distal sections of a foot that creates ideal conditions for possible reconstructive interference upon vessels and favors to prevent pathological effect of ischemized limb inclusion into blood flow. EFFECT: higher efficiency of therapy. 2 cl
This is a prospective, randomized, controlled, double-blind, 2-arm parallel-group clinical trial in the Philippines. Subjects will be recruited from a single centre; in case of insufficient recruitment, more sites will be added to the study. The clinical trial is composed of two parts: a double-blind interventional period and a follow-up period. The first period is the double-blind intervention phase from enrolment (V1) until age 12 months (V5). The intervention will be provided only during this double-blind phase. The second period is a non-interventional follow-up period from age 12 months until age 24 months.
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. The recommended phase 2 dose (RP2D) and schedule of RX-3117, in combination with Abraxane®, will be determined based on the safety profile, dose modification, and pharmacokinetics (PK). Phase 1 will be conducted using a combination of the single agent maximum tolerated dose (MTD) for RX-3117 and the Abraxane dose as per the package insert for patients with pancreatic cancer in combination with gemcitabine.

After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy. Approximately 10 subjects will participate in the Stage 1 at the dose identified in Phase 1 (RP2D). Subjects will be treated for up to 8 cycles of combined therapy. An interim analysis will be conducted after 10 evaluable subjects have been treated at the RP2D, have completed a minimum of 4 cycles of therapy, or have discontinued therapy due to progressive disease before completing 4 cycles. If an adequate number of Responders are observed out of the initial 10 evaluable subjects, then 40 additional subjects will be enrolled to participate in Stage 2. Subjects will be treated for up to 8 cycles of combined therapy.
The invention relates to a traditional Chinese medicine formula for treating chronic proctitis. Proctitis is caused by careless diets, such as excessive drinking and overeating of strong excitant food, inappropriate long-term taking of weight losing medicament, excessive corrosive medicament in anus and bacteria infection. A light patient only has mucosa inflammation, and a severe patient has inflammations involving submucosa, muscular layer even rectum surrounding tissues; sometimes, part of the rectum mucosa is inflammatory, and sometimes the whole rectum mucosa or even colon mucosa are inflammatory. Proctitis is always seen in weak physique and resistance and after diseases of heart, lung, liver and gastrointestinal tract, respiratory tract infection, infectious disease; and constipation, diarrhoea, hemorrhoid, anorectal prolapse, anal fistula, polyposis, anorectal stenosis, rectum tumour, rectum damage and foreign matter all can cause proctitis. Severe patients need to be treated immediately. Prior proctitis treatment method is no more than a final operation, which causes huge pains in patient body and energy.
A liquid having a water content of less than 20 wt.% is encapsulated within a membrane. The membrane comprises an extract derivable from seaweed. The liquid may be water-, glycerine or oil-based. The extract may be carrageenan, agar or a cellulose polymer, preferably hydroxypropyl methyl cellulose (HPMC). The membrane or liquid may comprise an additive, emulsifier, diluent, carrier, flavouring, fragrance and/or preservative. The liquid may be edible and/or suitable for applying to a body part. The liquid may comprise a personal hygiene or cosmetic product, e.g. shower gel, shampoo, conditioner, cream, sun cream, skin cream or toothpaste, or may comprise a food or drink product, e.g. a sauce, oil, condiment, energy gel or coffee. The liquid may comprise a single dose, and/or may have a volume of 0.1 to 30 ml. The membrane may be a soft gel capsule or film. A method of preparing the encapsulated liquid is also claimed, comprising the steps of (i) providing a solution of seaweed-derived extract, (ii) pumping the solution through a die to create two gel ribbons or films, (iii) injecting the liquid between the ribbons/films, and (iv) sealing the ribbons/films around the liquid to form the liquid encapsulated within a membrane.
OBJECTIVES: Intussusception is the invagination of a proximal segment of the intestine into a more distal segment. The present study aimed to determine the sensitivity of the ischemia-modified albumin (IMA) and the correlation between IMA and the severity of intestinal ischemia in intussusception cases.
METHODS: Thirty-six consecutive children aged between 0 and 16 years presenting with the clinical and radiological features of intestinal obstruction caused by intussusception were enrolled in the study. The age- and sex-matched control group was composed of patients undergoing outpatient surgery. The patients were categorized as cases of type I (ileoileal), type II (ileocecal), and type III (colocolic) based on the ultrasonography findings.
RESULTS: The mean IMA level of the intussusception group was 179.13 ± 220.33 ng/mL, whereas the mean level was found as 89 ± 70.9 ng/mL in the control group. When the patients were categorized as ileoileal, ileocecal, and colocolic, the mean IMA levels were detected as 235.65 ± 268.14 ng/mL, 174.46 ± 212.8 ng/mL, and 46.95 ± 19.56 ng/mL, respectively. There was a moderate correlation between the invaginated segment lengths measured by the surgeon during the operation and IMA levels.
CONCLUSIONS: Our study findings reveal that IMA can be used as an auxiliary diagnostic marker in patients presenting with symptoms and signs suggestive of intussusception. Thus, patients can be screened for mechanical bowel obstruction due to intussusception and may be referred to pediatric surgery centers earlier for further examination.
Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
The worldwide HIV/AIDS epidemic may only be controlled through the development of a safe and effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct, readily produced in large quantities, and stable for long periods of time. EP HIV-1090 is a DNA HIV CTL vaccine; the proteins for which its genes code are designed to interact with CD8 cells (CTL) and cause CD8 cell proliferation. The DNA plasmids in EP HIV-1090 code for proteins conserved among HIV subtypes A, B, C, D, F, and G, which encompass the HLA subtypes of 85% of the worldwide general population.

Participants will be enrolled in this study for 1 year. Group 4 participants will receive EP HIV-1090 or placebo at study entry and Months 1, 3, and 6. There will be 11 study visits that will occur at screening; study entry; and Months 0.5, 1, 1.5, 3, 3.5, 6, 6.5, 9, and 12. A physical exam and risk reduction/pregnancy prevention counseling will occur at each visit. Participants will be asked about their adverse experiences from vaccination at each visit. Blood and urine collection will occur at selected visits.
BACKGROUND: Bariatric surgeries may affect the pharmacokinetics of medications through alterations of the gastrointestinal physiology. Pharmacokinetic changes of first-line antiseizure medications such as lamotrigine and valproate following bariatric treatment have received little research attention so far.
METHODS: In our prospective case study we included lamotrigine- or valproate-treated patients undergoing bariatric surgery at hospitals in Central Norway. Lamotrigine and valproate concentrations were assessed using serial blood samples over a dose interval, before and one, six and twelve months following surgery. Primary outcomes included changes in area under the time-concentration curve (AUC) with secondary outcomes comprising full pharmacokinetic profiling.
RESULTS: Six lamotrigine-treated obese patients undergoing Roux-en-Y gastric bypass (RYGB) (n = 3) and sleeve gastrectomy (SG) (n = 3), as well as two valproate-treated patients (one undergoing RYGB and one SG) were included. Largest changes for dose-adjusted AUC values after surgery were seen in RYGB-treated patients on lamotrigine (average increases of 38 % one month and 32 % 12 months postoperatively). In the patients on valproate, AUC values were decreased by 22 % after 6 months and by 30 % after 12 months. The interindividual variation was high. Formal statistical testing was not done due to few cases.
CONCLUSION: Postoperative pharmacokinetic changes for lamotrigine and valproate were modest, but for lamotrigine changes may be larger in patients undergoing RYGB than in those undergoing SG. Given the substantial interindividual variation, therapeutic drug monitoring should be used to capture pharmacokinetic changes and guide dose adjustments after bariatric surgery.
Participants with confirmed TB will start treatment and have a follow-up visit soon after to check their TB symptoms again and collect blood samples. They will also have a second follow-up visit at week 26 to assess their treatment progress and TB status.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to restorative medicine, physiotherapy, and can be used for treating occupational stress. That is ensured by applying cathodes on the forehead region and anodes on mastoid processes. Gaskets under electrodes are soaked with water. Gaskets on anodes are additionally wetted with 2 ml of 1 % solution of serotonin adipinate. Contact is exposed to constant bipolar electric current in form of a sequence of rectangular pulses, current intensity from 0.2 to 2 mA until light sensations of tingling on skin under the location of electrodes. Constant component of electric current is used in ratio 1:5 with pulse component. Current frequency 77.5 Hz in frequency modulation mode ±2.5 Hz. Duration of pulses duration is 3 ms. Duration of procedure is 20 minutes, therapeutic course is 5 days. Musical-speech suggestion accompanying is performed. Additionally, aminalol tablets are orally administered.EFFECT: method provides higher effectiveness of restorative treatment ensured by intensified anti-stress effects of transcranial electric stimulation as a result of complex direct synergetic action in declared doses and regimens for opioidergic, serotoninergic, GABA-dopaminergic stress-relieving systems.1 cl, 2 tbl
The present invention relates to nanoparticles comprising drug dimers and uses thereof. In additional, the nanoparticles may further include fucoidan. The nanoparticles containing an obeticholic acid dimeric compound can be used to treat liver diseases. The nanoparticles containing the drug dimers of the present invention can increase a drug content and improve the dispersibility of the drug. In additional, the targeting efficiency of the nanoparticles was increased. Therefore, effective pharmacological effects can be obtained using less drugs to have excellent commercial applicability.
PCT No. PCT/DE88/00370 Sec. 371 Date Apr. 3, 1989 Sec. 102(e) Date Apr. 3, 1989 PCT Filed Jun. 21, 1988 PCT Pub. No. WO89/00437 PCT Pub. Date Jan. 26, 1989.The invention relates to a transdermal therapeutic system for administering or applying active substances to the skin with a backing layer remote from the skin, an active substance depot, an active substance delivery control means controlling the delivery of the active substance through the system and a contact adhesive means for fixing the therapeutic system to the skin, in which the active substance depot is a multichamber system, in which discreet chambers contain one or more active substances.